Activin/myostatin type II receptor drugs for Obesity
4 tracked Activin/myostatin type II receptor drugs in the Obesity race. The class explanation lives on the Activin/myostatin type II receptor page; the full indication pipeline across every mechanism is on the Obesity page.
2 Phase 22 Phase 1
Head-to-head evidence: AZD1043 vs bimagrumab · bimagrumab vs REGN20934 · bimagrumab vs taldefgrobep alfa